| Description | ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. |
| molecular weight | 572.6 |
| Molecular formula | C24H31F3N6O5S |
| CAS | 220519-07-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |